NASDAQ:NKTR Nektar Therapeutics - NKTR Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nektar Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. $0.70 +0.07 (+11.06%) (As of 03/31/2023 12:00 AM ET) Add Compare Share Share Today's Range$0.62▼$0.7150-Day Range$0.64▼$3.1552-Week Range$0.60▼$6.26Volume16.15 million shsAverage Volume3.85 million shsMarket Capitalization$133.01 millionP/E RatioN/ADividend YieldN/APrice Target$3.08 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Nektar Therapeutics MarketRank™ ForecastAnalyst RatingHold1.50 Rating ScoreUpside/Downside338.7% Upside$3.08 Price TargetShort InterestHealthy3.74% of Shares Sold ShortDividend StrengthN/ASustainability-1.77Upright™ Environmental ScoreNews Sentiment0.66Based on 4 Articles This WeekInsider TradingSelling Shares$121,158 Sold Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.49 out of 5 starsMedical Sector152nd out of 1,004 stocksPharmaceutical Preparations Industry62nd out of 489 stocks 2.8 Analyst's Opinion Consensus RatingNektar Therapeutics has received a consensus rating of Hold. The company's average rating score is 1.50, and is based on no buy ratings, 3 hold ratings, and 3 sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $3.08, Nektar Therapeutics has a forecasted upside of 338.7% from its current price of $0.70.Amount of Analyst CoverageNektar Therapeutics has only been the subject of 4 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted3.74% of the outstanding shares of Nektar Therapeutics have been sold short.Short Interest Ratio / Days to CoverNektar Therapeutics has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Nektar Therapeutics has recently decreased by 19.09%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldNektar Therapeutics does not currently pay a dividend.Dividend GrowthNektar Therapeutics does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreNektar Therapeutics has received a 60.23% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Topoisomerase 1 (TOP1) inhibitors", "Clinical research services", and "Peripheral opioid receptor antagonists" products. See details.Environmental SustainabilityThe Environmental Impact score for Nektar Therapeutics is -1.77. Previous Next 3.7 News and Social Media Coverage News SentimentNektar Therapeutics has a news sentiment score of 0.66. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.51 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Nektar Therapeutics this week, compared to 2 articles on an average week.Search Interest13 people have searched for NKTR on MarketBeat in the last 30 days. This is an increase of 44% compared to the previous 30 days.MarketBeat Follows5 people have added Nektar Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Nektar Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $121,158.00 in company stock.Percentage Held by InsidersOnly 3.38% of the stock of Nektar Therapeutics is held by insiders.Percentage Held by Institutions92.30% of the stock of Nektar Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Nektar Therapeutics are expected to remain at ($0.89) per share in the coming year.Price to Earnings Ratio vs. the MarketThe P/E ratio of Nektar Therapeutics is -0.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Nektar Therapeutics is -0.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNektar Therapeutics has a P/B Ratio of 0.36. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Nektar Therapeutics (NASDAQ:NKTR) StockNektar Therapeutics is a research-based biopharmaceutical company which engages in discovering and developing medicines in areas of unmet medical need. Its research and development pipeline of new investigational drugs includes therapies for oncology, immunology and virology. The firm focuses on using new chemistry approaches to make medicines to treat cancer and autoimmune diseases. The company was founded in 1990 and is headquartered in San Francisco, CA.Read More Receive NKTR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nektar Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address NKTR Stock News HeadlinesMarch 30, 2023 | finance.yahoo.comWhy Is Nektar (NKTR) Down 51.9% Since Last Earnings Report?March 27, 2023 | thestreet.comNektar Therapeutics Inc. Stock Downgraded By TheStreet Ratings (NKTR)April 1, 2023 | Legacy Research (Affiliate) (Ad)Stocks are for suckers – try this insteadThis has nothing to do with dividends, day trading... taking out a loan... or anything like that. What you need is about 3 seconds to execute this simple financial maneuver...March 24, 2023 | finance.yahoo.comNektar (NKTR) Upgraded to Buy: Here's WhyMarch 24, 2023 | americanbankingnews.comBrokerages Set Nektar Therapeutics (NASDAQ:NKTR) PT at $3.08March 22, 2023 | finance.yahoo.comDown -69.13% in 4 Weeks, Here's Why You Should You Buy the Dip in Nektar (NKTR)March 14, 2023 | finance.yahoo.comSage Therapeutics, Inc. (SAGE) Soars 9.6%: Is Further Upside Left in the Stock?March 6, 2023 | markets.businessinsider.comAnalyst Ratings for Nektar TherapeuticsApril 1, 2023 | Legacy Research (Affiliate) (Ad)Sell every Stock except ONE Markets are down...But Jeff Clark couldn't care less because he ignores almost every stock in the market except ONE. He lives financially free trading this One Stock Once per month...March 6, 2023 | msn.comNektar Therapeutics Earnings Perspective: Return On Capital EmployedFebruary 28, 2023 | msn.comNektar Therapeutics GAAP EPS of -$0.32 beats by $0.13, revenue of $22.02M misses by $0.19MFebruary 26, 2023 | seekingalpha.comNektar Therapeutics: Another Clinical Failure Nearly Wipes Out The R&D ValueFebruary 25, 2023 | seekingalpha.comNektar Therapeutics plunges 29% after hours on mid-stage lupus treatment failureFebruary 24, 2023 | investorplace.comWhy Is Nektar Therapeutics (NKTR) Stock Down 39% Today?February 24, 2023 | msn.comNektar Plunges after Topline Data Misses Primary EndpointFebruary 24, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Vapotherm (VAPO) and Nektar Therapeutics (NKTR)February 23, 2023 | finance.yahoo.comNektar Therapeutics Announces Phase 2 Topline Data for Rezpegaldesleukin in Patients with Systemic Lupus ErythematosusFebruary 23, 2023 | reuters.comNektar Therapeutics' autoimmune disease drug fails mid-stage studyFebruary 18, 2023 | seekingalpha.comNektar Therapeutics Looking To Rebuild Faith In Its Now Early-Stage PipelineFebruary 1, 2023 | technews.tmcnet.comGlancy Prongay & Murray LLP Announces Investigation of Nektar Therapeutics (NKTR)January 4, 2023 | finance.yahoo.comNektar Therapeutics' President and CEO, Howard Robin, To Present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, CADecember 23, 2022 | reuters.comNKTR.O - Nektar Therapeutics | Stock Price & Latest News | ReutersDecember 13, 2022 | markets.businessinsider.comMizuho Securities Reaffirms Their Hold Rating on Nektar Therapeutics (NKTR)December 12, 2022 | finance.yahoo.comNektar Announces Poster Presentations at the 64th American Society of Hematology (ASH) Annual MeetingNovember 18, 2022 | seekingalpha.comNektar Therapeutics: Recovery Seems To Be A MirageNovember 10, 2022 | finance.yahoo.comNektar Therapeutics Third Quarter 2022 Earnings: Beats ExpectationsNovember 10, 2022 | finance.yahoo.comNektar Therapeutics Presents Preclinical Data from Novel PEGylated Interferon Gamma Program, NKTR-288, at the Society for Immunotherapy of Cancer (SITC) Annual MeetingSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive NKTR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nektar Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address NKTR Company Calendar Last Earnings2/28/2023Today4/01/2023Next Earnings (Estimated)5/04/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals SectorMedical Current SymbolNASDAQ:NKTR CUSIP64026810 CIK906709 Webwww.nektar.com Phone(415) 482-5300Fax415-339-5300Employees740Year Founded1990Price Target and Rating Average Stock Price Forecast$3.08 High Stock Price Forecast$6.00 Low Stock Price Forecast$1.50 Forecasted Upside/Downside+338.7%Consensus RatingHold Rating Score (0-4)1.50 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.97) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-368,200,000.00 Net Margins-399.98% Pretax Margin-396.48% Return on Equity-76.92% Return on Assets-42.03% Debt Debt-to-Equity RatioN/A Current Ratio8.00 Quick Ratio7.72 Sales & Book Value Annual Sales$92.06 million Price / Sales1.44 Cash FlowN/A Price / Cash FlowN/A Book Value$1.95 per share Price / Book0.36Miscellaneous Outstanding Shares189,235,000Free Float182,839,000Market Cap$133.01 million OptionableOptionable Beta1.10 Social Links Key ExecutivesHoward W. RobinPresident, Chief Executive Officer & DirectorJillian B. ThomsenChief Financial Officer & Senior Vice PresidentJonathan ZalevskyChief Research & Development OfficerBrian L. KotzinChief Medical Officer & Senior Vice PresidentMary TagliaferriChief Development Officer & Senior Vice PresidentKey CompetitorsParatek PharmaceuticalsNASDAQ:PRTKAssembly BiosciencesNASDAQ:ASMBOmerosNASDAQ:OMERReneo PharmaceuticalsNASDAQ:RPHMMilestone PharmaceuticalsNASDAQ:MISTView All CompetitorsInsiders & InstitutionsAcrisure Capital Management LLCBought 72,131 shares on 3/28/2023Ownership: 0.038%Voya Investment Management LLCBought 44,817 shares on 2/28/2023Ownership: 0.134%Howard W RobinSold 19,635 sharesTotal: $58,905.00 ($3.00/share)Alliancebernstein L.P.Sold 765,596 shares on 2/16/2023Ownership: 0.252%Jillian B ThomsenSold 10,267 sharesTotal: $30,801.00 ($3.00/share)View All Insider TransactionsView All Institutional Transactions NKTR Stock - Frequently Asked Questions Should I buy or sell Nektar Therapeutics stock right now? 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Nektar Therapeutics in the last twelve months. There are currently 3 sell ratings and 3 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" NKTR shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NKTR, but not buy additional shares or sell existing shares. View NKTR analyst ratings or view top-rated stocks. What is Nektar Therapeutics' stock price forecast for 2023? 6 Wall Street analysts have issued 1 year price targets for Nektar Therapeutics' stock. Their NKTR share price forecasts range from $1.50 to $6.00. On average, they expect the company's stock price to reach $3.08 in the next year. This suggests a possible upside of 338.7% from the stock's current price. View analysts price targets for NKTR or view top-rated stocks among Wall Street analysts. How have NKTR shares performed in 2023? Nektar Therapeutics' stock was trading at $2.26 at the start of the year. Since then, NKTR shares have decreased by 68.9% and is now trading at $0.7029. View the best growth stocks for 2023 here. Are investors shorting Nektar Therapeutics? Nektar Therapeutics saw a decline in short interest during the month of March. As of March 15th, there was short interest totaling 7,080,000 shares, a decline of 19.1% from the February 28th total of 8,750,000 shares. Based on an average daily trading volume, of 2,430,000 shares, the short-interest ratio is currently 2.9 days. View Nektar Therapeutics' Short Interest. When is Nektar Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023. View our NKTR earnings forecast. How were Nektar Therapeutics' earnings last quarter? Nektar Therapeutics (NASDAQ:NKTR) released its quarterly earnings results on Tuesday, February, 28th. The biopharmaceutical company reported ($0.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.43) by $0.11. The biopharmaceutical company had revenue of $22.02 million for the quarter, compared to the consensus estimate of $22.21 million. Nektar Therapeutics had a negative net margin of 399.98% and a negative trailing twelve-month return on equity of 76.92%. Nektar Therapeutics's revenue for the quarter was down 11.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.79) earnings per share. What ETFs hold Nektar Therapeutics' stock? ETFs with the largest weight of Nektar Therapeutics (NASDAQ:NKTR) stock in their portfolio include Virtus LifeSci Biotech Products ETF (BBP), Invesco S&P SmallCap Health Care ETF (PSCH), Invesco Nasdaq Future Gen 200 ETF (QQQS) and Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL).AdvisorShares Dorsey Wright Short ETF (DWSH) and What is Howard W. Robin's approval rating as Nektar Therapeutics' CEO? 46 employees have rated Nektar Therapeutics Chief Executive Officer Howard W. Robin on Glassdoor.com. Howard W. Robin has an approval rating of 81% among the company's employees. What other stocks do shareholders of Nektar Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Nektar Therapeutics investors own include Micron Technology (MU), NVIDIA (NVDA), Alibaba Group (BABA), Gilead Sciences (GILD), Intel (INTC), Pfizer (PFE), Advanced Micro Devices (AMD), Bristol-Myers Squibb (BMY), Netflix (NFLX) and Incyte (INCY). What is Nektar Therapeutics' stock symbol? Nektar Therapeutics trades on the NASDAQ under the ticker symbol "NKTR." How do I buy shares of Nektar Therapeutics? Shares of NKTR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Nektar Therapeutics' stock price today? One share of NKTR stock can currently be purchased for approximately $0.70. How much money does Nektar Therapeutics make? Nektar Therapeutics (NASDAQ:NKTR) has a market capitalization of $133.01 million and generates $92.06 million in revenue each year. The biopharmaceutical company earns $-368,200,000.00 in net income (profit) each year or ($1.97) on an earnings per share basis. How many employees does Nektar Therapeutics have? The company employs 740 workers across the globe. How can I contact Nektar Therapeutics? Nektar Therapeutics' mailing address is 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA, 94158. The official website for the company is www.nektar.com. The biopharmaceutical company can be reached via phone at (415) 482-5300, via email at investors@nektar.com, or via fax at 415-339-5300. This page (NASDAQ:NKTR) was last updated on 4/1/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.